CIK: 0001750122
Total reported value
$238.9M
Reporting period: 2018-09-30 · Number of holdings: 13
Aquilo Capital Management, LLC disclosed 13 holdings in its latest 13F filing for the period ending 2018-09-30, with total reported value of $238.9M and a quarterly turnover rate of 87.1%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "A"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add XBI
+83.3% $104.1M
Trim N5749R100
+3.6% -$2.9M
Trim 548862101
-13.8% -$3.3M
Trim CTMX
+3.8% -$2.4M
Trim ADROEUR
+4.8% $1.4M
Trim PIRSEUR
0.0% $1.0M
Showing top 12 holdings (of 13 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 44.14% | +43.02% | +83.33% | |
| 2 | ✓ | Merus N V | Stock-Other | 10.70% | -12.78% | +3.58% | |
| 3 | ✓ | Loxo Oncology INC | Stock-Other | 7.82% | -10.32% | -13.80% | |
| 4 | FATE | Fate Therapeutics INC | Stock-Other | 6.71% | +1.28% | +69.69% | |
| 5 | ADROEUR | Chinook Therapeutics INC | Stock-Other | 6.48% | -5.11% | +4.85% | |
| 6 | ✓ | Synlogic INC | Stock-Other | 5.94% | +3.45% | +225.31% | |
| 7 | CTMX | Cytomx Therapeutics INC | Stock-Other | 5.22% | -7.03% | +3.85% | |
| 8 | PIRSEUR | Pieris Pharmaceuticals INC | Stock-Other | 4.63% | -3.63% | — | |
| 9 | SPRO | Spero Therapeutics INC | Stock-Other | 3.52% | -1.52% | +91.91% | |
| 10 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 3.27% | +3.27% | NEW | |
| 11 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 1.47% | -3.55% | -52.58% | |
| 12 | MOR2 | Morphosys AG Adr | Stock-Other | 0.10% | -0.15% | -9.13% |
Not enough priced holdings yet to compute performance
Not enough sector-mapped data yet
Aquilo Capital Management, LLC's most significant position changes for 2018-09-30: New buy: Xenon Pharmaceuticals INC (XENE); Sold out: Autolus Therapeutics PLC (AUTL); Sold out: Cellectis - Adr (CLLS); Sold out: Five Prime Therapeutics INC (FPRX); Add: Ss Spdr S&p Biotech ETF (XBI) — shares +83.33%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | +43% | +83.33% | Add |
| 2 | ✓ | Synlogic INC | +3.5% | +225.31% | Add |
| 3 | FATE | Fate Therapeutics INC | +1.3% | +69.69% | Add |
| 4 | MOR2 | Morphosys AG Adr | -0.2% | -9.13% | Trim |
| 5 | SPRO | Spero Therapeutics INC | -1.5% | +91.91% | Add |
| 6 | LKFT | Lakefront Biotherapeutic-adr | -3.6% | -52.58% | Trim |
| 7 | PIRSEUR | Pieris Pharmaceuticals INC | -3.6% | — | Unchanged |
| 8 | ADROEUR | Chinook Therapeutics INC | -5.1% | +4.85% | Add |
| 9 | CTMX | Cytomx Therapeutics INC | -7% | +3.85% | Add |
| 10 | ✓ | Loxo Oncology INC | -10.3% | -13.80% | Trim |
| 11 | ✓ | Merus N V | -12.8% | +3.58% | Add |
| 12 | XENE | Xenon Pharmaceuticals INC | — | NEW | New buy |
| 13 | AUTL | Autolus Therapeutics PLC | — | EXIT | Sold out |
| 14 | CLLS | Cellectis - Adr | — | EXIT | Sold out |
| 15 | FPRX | Five Prime Therapeutics INC | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0002068112
Total reported value
$238.9M
162 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001599795
Total reported value
$238.9M
109 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001986457
Total reported value
$239.0M
66 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0000096223
Total reported value
$14.6B
1,692 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0000860645
Total reported value
$83.5M
21 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0000924020
Total reported value
$978.2M
21 stks
2021-06-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Fate Therapeutics INC